epitomee®

Business Focus & Growth Strategy US Weight Management Market



Investor Presentation

October 2026

TASE: EPIT

Disclaimer

This presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the “Company”) and should not be regarded as a recommendation or an opinion on such matters. The information included in this Presentation is not comprehensive and does not include all the information with respect to the Company and its business as may be required for any decision concerning an investment in the Company’s securities. This Presentation includes forecasts, estimates, assessments, expectations and other information, intent or belief pertaining to future events and/or matters, which constitute “forward-looking statements” as defined in the Securities Law 5728-1968, which is based on current expectations, projections and assumptions about future events. Actual results may differ materially due to a variety of factors, some of which the Company has no control over and cannot be reasonably foreseen at this date, including, but not limited to: dependency on third parties engaged by, or who contract, the Company and its services, change in the overall economy; and geopolitical events and their impact on the Company and on local and global economy, including effects and disruptions to shipping and supply chain, as well as the other risk factors detailed in Section 24 of Part A of the Company’s 2025 annual report and subsequent periodic reports. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Therefore, actual future results, performances or achievements of the Company may differ, including in a material manner, from what is or may be expressed or implied in this Presentation. Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources. The accuracy of such information and the assumptions on which such information is based have not been independently verified. The past performance information contained herein is not indicative of future results and there can be no assurance that the Company will achieve comparable results or that the Company will be able to implement or achieve its strategy. All information presented is proprietary information of Epitomee Medical.

Information as of the Presentation Date. This presentation and the related webinar, including any statements made during the question-and-answer session, speak only as of October 26 2026 (the “Presentation Date”). The webinar is being recorded, and the recording and this presentation will be made available on the Company’s website. Information contained herein may change after the Presentation Date and should not be relied upon as current at any later time. Except as required by applicable law, the Company undertakes no obligation to update or revise any information, including forward-looking statements, whether as a result of new information, future events or otherwise.

Public reports. This presentation should be read together with the Company’s periodic and immediate reports filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, including the Company’s 2025 Annual Report and its report for the six months ended June 30, 2026.

Product information. The Epitomee® capsule is a prescription (Rx-only) medical device, FDA-cleared to aid in weight management in adults with overweight or obesity with a Body Mass Index (BMI) of 25-40 kg/m², when used in conjunction with diet and exercise. It is CE-marked and registered with the Israeli Ministry of Health (AMAR). For contraindications, warnings and precautions, see the Instructions for Use. This presentation is intended for investors and does not constitute medical advice or promotional material.

Cross-study comparisons. No head-to-head clinical studies have compared the Epitomee® capsule with GLP-1 receptor agonists or other weight-management therapies. Data from different studies are not directly comparable due to differences in study design, populations and endpoints.

Third-party information. Information regarding the Company’s commercial partners, including ReviveHealth and Rafa, and any timelines attributed to them, is based on information provided by those parties and has not been independently verified. Such timelines are estimates and may change.

Illustrative figures. Capacity, patient and revenue figures in this presentation are illustrative only, are based on management assumptions, and do not constitute a forecast, target or guidance. Capacity beyond the levels planned for 2027 requires additional capital expenditure and is subject to funding.

Investment Highlights

Epitomee is leveraging its hydrogel scaffold technology to commercialize an FDA-cleared weight-management medical device and to develop a future drug-delivery pipeline

1

FDA-cleared, non-drug Rx capsule

FDA-cleared, CE-marked and registered with AMAR, for adults with BMI 25-40; mechanical action, no drug or hormones

2

Clinically demonstrated efficacy

RESET: 6.6% vs. 4.6% mean weight loss (p = 0.0054); ×2.5 more patients lost ≥10% (27% vs. 11%). ELECT extension: selected RESET participants (completed 24 weeks on Epitomee®, ≥3% weight loss) maintained 11.2% through week 48

3

Placebo-level GI tolerability

All GI events 39% vs. 40% with placebo; 1.4% stopped due to side effects (vs. 3.5% with placebo)

4

Large, underserved market

Global weight-management market of ~$180B (2025), projected to grow to ~$400B by 2035; segments underserved by GLP-1 drugs

5

Commercial launch underway

Israel launched with Rafa; US: B2B channel opened with first partner ReviveHealth (agreements signed) and DTC telehealth platform launched (mid Oct 2026); bespoke marketing strategy per geography (US, Israel, EU)

6

Scalable in-house manufacturing

In-house manufacturing with a staged scale-up plan to support commercial growth; expansion beyond the 2027 plan is subject to funding

BACKED BY Shimon Eckhouse (co-founder) and investors from the XT group

epitomee

Weight-management market: Towards Healthcare, Weight Management Market report 2026. Note: Market size estimates vary significantly depending on source and what is included in each assessment. Multiple estimations exist; the figures in this presentation represent general trends and should be used as directional guidance only.

Experienced Management Team Positioned for US Commercial Entry



Shimon Eckhouse, PhD

Co-founder, Chairman and largest shareholder

Founder of Syneron NASDAQ: ELOS & Lumenis
NASDAQ: LMNS, Sofwave Medical TLV: SOFW and others



Dolev Rafaeli, PhD

Chief Executive Officer

CEO Radiancy Inc;
CEO PhotoMedex Inc (NASDAQ: PHMD);
CEO and Vice Chair Strata Skin Sciences (NASDAQ: SSKN)



Gal Aharonowitz

Chief Operating Officer

SHL, VP R&D Lumenis, GM Israel
Dune Medical



Moran Tabak

Chief Revenue Officer

Passiflora LTD
PhotoTherapeutics LTD
Radiancy Inc
PhotoMedex Inc (NASDAQ: PHMD)



Gil Cohen, PhD

VP R&D

CSO Dune Medical Devices, Hebrew University of Jerusalem



Maya Gabrieli, CPA

Chief Financial Officer

Plastopil Hazorea LTD, KPMG



Hadas Ashkenazi Stapler

VP Quality Assurance and Regulatory Affairs

Ventor - Medtronic, Keystone Heart, Impliant



Alon Heth

VP Sales and Marketing

VP at Human Xtensions, B-Cure Laser, Elscint


epitomee

Epitomee® Capsule Designed to Meet Rapidly Rising Demand for Weight Management Products

GROWTH DRIVERS

This growth is driven by rising obesity rates and advancements in weight management products.

Source: IQVIA Institute, July 2025



Note: Market size estimates vary significantly depending on source and what is included in each assessment. Multiple estimations exist; the figures in this presentation represent general trends and should be used as directional guidance only.

The GLP-1 Weight-Maintenance Gap: An Opportunity for Epitomee®

65%

of patients without type 2 diabetes (non-T2D) stop GLP-1s within 12 months[1]

2/3

of prior weight loss regained within 1 year of stopping semaglutide[2]; other studies show similar regain[3,4]

1 in 12

are still taking a GLP-1 at 3 years[7]

Up to 74%


experience GI side effects on GLP-1 (vs. 48% on placebo)[5]; serious GI complications up to ×9 more likely (vs. bupropion-naltrexone)[6]

Post GLP-1 users require weight maintenance.

epitomee

1 - Rodriguez et al., JAMA Netw Open 2025
2 - Wilding et al., Diabetes Obes Metab 2022
3 - West et al., The BMJ, Jan 2026
4 - SURMOUNT-4, Aronne et al., JAMA 2024
5 - Wilding et al., NEJM 2021
6- Sodhi et al., JAMA 2023
7 - Prime Therapeutics, June 2025 (pharmacy-claims analysis; not peer-reviewed)

Epitomee Targeting U.S. Market of 172 Million Eligible Patients



- **Epitomee® Entry Market SOM**: patients aligned with Epitomee® value proposition (seeking up to 10% weight loss, maintenance or intolerant to GLP-1)
- **Patients with mild/no comorbidities**: patients with severe comorbidities[1] likely to seek Tx addressing comorbidity
- **Eligible patients TAM:** US adult population overweight & obese class I/II[2]

1. Severe comorbidities: diabetes, hypertension, OSA | Source: BCG analysis commissioned by the Company (June 2024)
2. Epitomee® is FDA-cleared for adults with BMI 25-40 kg/m². Should not be used in: pregnancy, allergy to any component, prior gastric sleeve or bypass, gastroparesis, or GERD. See Instructions for Use for additional precautions.

epitomee®

Note: Market size estimates vary significantly depending on source and what is included in each assessment. Multiple estimations exist; the figures in this presentation represent general trends and should be used as directional guidance only.

The Epitomee® Capsule



epitomee®
weight management capsule

The Epitomee® Capsule's Unique Mechanism of Action Provides a Non-Drug Alternative to GLP-1

1	2	3	4
Ingest	**Expand**	**Satiate**	**Disintegrate**
Epitomee® Capsule ingested with water before a meal	Hydrogel scaffold expands in stomach	Expanded hydrogel provides feeling of durable satiation and fullness to reduce hunger	Hydrogel scaffold disintegrates in the small intestine and is excreted naturally



NON-DRUG MODE OF ACTION Mechanical action in the stomach: no drug, no hormones, and not absorbed into the bloodstream



epitomee®

Epitomee® Capsule Is FDA-Cleared, CE-Marked and Registered with AMAR

A non-drug, clinically proven capsule that, by expanding in the stomach, helps users feel full, eat less, and stay on track





- ✓ Rx device for adults with BMI 25-40*
- ✓ No serious device-related adverse events reported
- ✓ Integrates seamlessly into diet & exercise routines[1,2]

Dosing

Take one capsule, twice daily, with two 8-ounce glasses of water (approximately 500 ml in total), ~30 minutes before lunch and dinner

Program

The Epitomee® capsule is indicated for use alongside diet and physical activity

epitomee® weight management capsule

*Including adults below GLP-1 drug thresholds (GLP-1 drugs are FDA-approved for adults with BMI ≥30, or ≥27 with a weight-related condition).

1. Ard JD, Ryan DH, O'Neil PM, et al. Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study. Obesity. 2025;33(3):500-511. 2. Kamar M, Ryan DH, Leonard S, et al. The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: the ELECT extension study. Obesity Pillars. 2025;16:100216.

ELECT Participants Maintained 11.2% Mean Weight Loss Through Week 48

Weight loss maintained through Week 48; no serious adverse events reported in the extension


11.3% → 11.2%

Mean weight loss at Week 24 and Week 48 in ELECT participants

A SELECTED COHORT

Not all RESET participants continued: only selected participants who completed 24 weeks on Epitomee® and lost at least 3% joined the extension.

They had lost 11.3% at Week 24 and, with 24 additional weeks of Epitomee® and lifestyle counseling, maintained 11.2% at Week 48.



Dotted line: RESET placebo participants who joined the extension and switched to the Epitomee® Capsule at Week 24

epitomee® weight management capsule

Kamar M, Ryan DH, Leonard S, et al. The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: the ELECT extension study. Obesity Pillars. 2025;16:100216.

Predictable Results: Know by Week 8 Who Will Benefit

In RESET, a patient's weight loss after 8 weeks on Epitomee® predicted the result at 24 weeks

WEEK 8 CHECK

Lost at least 2% of body weight?

YES: about two in three patients (64.5%)

9.3%

average weight loss by week 24

NO: the remaining patients

0.8%

average weight loss by week 24, so the physician can reassess early

95.5% of patients who missed the week-8 mark also did not reach 5% weight loss by week 24

Why it matters: an early, objective checkpoint lets physicians focus treatment on patients likely to succeed, which supports patient satisfaction and retention in a direct-to-consumer model.

Analysis performed after the RESET trial was completed (post hoc). Source: Jakicic et al., Clinical Obesity 2026.

epitomee®
weight management capsule

Tolerability Is Epitomee®'s Edge Over GLP-1 Drugs

	Epitomee® capsule (medical device)	GLP-1 drugs (e.g., Wegovy®, Zepbound®, Foundayo™)
How it works	Mechanical: a gel expands in the stomach to create a feeling of fullness; not absorbed into the body	Hormonal: a drug absorbed into the bloodstream that acts on appetite and digestion
How it is taken	1 capsule with two glasses of water, 30 minutes before lunch and dinner	Weekly injection, or one pill a day
Dose adjustment	None: same dose from day 1	Dose increased gradually over 4-5 months
Indication	FDA-cleared indication: adults with BMI 25-40	FDA-approved: adults with BMI ≥30, or ≥27 with a weight-related condition
Digestive (GI) side effects	**All GI events: 39% vs. 40% with placebo (device-related: 26.8% vs. 31.9%)**	Wegovy®: nausea 44% vs. 16%, vomiting 25% vs. 6%, diarrhea 30% vs. 16%; all GI events 74.2% vs. 47.9%
Stopped due to side effects	**1.4% vs. 3.5% with placebo**	Wegovy®: 6.8% vs. 3.2% (weight-management trials); 16% vs. 8% over ~3 years (cardiovascular outcomes trial). Foundayo™: 8% vs. 3%
Serious adverse events	**No device-related serious adverse events in RESET (24 weeks); no serious adverse events in the ELECT extension (to 48 weeks)**	Label warnings include pancreatitis, gallbladder disease and kidney injury
FDA boxed warning (most serious)	**None**	Risk of thyroid C-cell tumors (Wegovy®, Zepbound®, Foundayo™)


Each product vs. its own placebo group, per published trials and U.S. labels; trial durations differ (Epitomee® 24 weeks; Wegovy® weight-management trials 68 weeks; cardiovascular outcomes trial median ~3 years). No head-to-head studies. Sources: Epitomee® U.S. Physician IFU (Dec 2025); Ard et al., Obesity 2025 (RESET); Kushner et al., Int J Obes 2026; Kamar et al., Obes Pillars 2025 (ELECT); Wilding et al., NEJM 2021 (STEP 1); Wegovy®, Zepbound® and Foundayo™ U.S. prescribing information. Trademarks belong to their respective owners.

epitomee®
weight management capsule

Additional Epitomee® Health Benefits in Peer-Reviewed Literature



Early response[3]



Waistline reduction[2,5]



Weight management[1-6]



Improved Quality of life[4]



Improvement in Metabolic syndrome[2]



Improvements in cardiometabolic risk factors[2]



Safe & drug-free[1-6]

1. **Ard JD, Ryan DH, O'Neil PM, et al.** Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study. *Obesity (Silver Spring).* 2025;33(3):500-511.
2. **Bays HE, et al.** Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: prespecified and exploratory analysis of the Epitomee capsule RESET study. *Obesity Pillars.* 2025;13:100163.
3. **Jakicic JM, Ryan DH, Ard JD, et al.** Association of the early response to an oral shape-shifting superabsorbent hydrogel capsule with weight loss. *Clinical Obesity.* 2026;16(1):e70037.
4. **Kushner RF, et al.** Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results. *International Journal of Obesity.* 2026;50(1):159-165.
5. **Kamar M, Ryan DH, Leonard S, et al.** The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: the ELECT extension study. *Obesity Pillars.* 2025;16:100216.
6. **Srivastava G, et al.** A novel approach to weight loss in women over 50 years: insights from the RESET study with a shape-shifting hydrogel capsule. *Diabetes Technology and Obesity Medicine.* 2026. doi:10.1177/29986702251408809.

epitomee®
weight management capsule

US Market Entry Strategy

TWO CHANNELS

1. **Direct-to-Consumer Telehealth**
2. **B2B Partnerships**

epitomee
weight management capsule

Potential Segments Underserved by Current Weight-Management Options

PATIENTS WHO DISCONTINUED GLP-1 DRUGS

Stopped GLP-1 treatment

65% of patients without type 2 diabetes stop GLP-1 drugs within a year; moderate-to-severe GI side effects were associated with higher discontinuation

Epitomee® fit: GI side effects at placebo level (All GI events 39% vs. 40%)

Potential role; not yet studied in this group

Maintain weight loss after GLP-1 treatment

Patients who stop typically regain about two-thirds of the weight they lost within a year

Epitomee® fit: In the ELECT extension, selected RESET participants (completed 24 weeks, ≥3% weight loss) who continued Epitomee® for 24 more weeks maintained their weight loss (11.3% at week 24; 11.2% at week 48)

Potential role; not yet studied in this group

PATIENTS NOT FULLY SERVED BY CURRENT OPTIONS

Below drug thresholds

BMI 25-27, or 27-30 without a weight-related condition: not eligible for prescription weight-loss drugs

Epitomee® fit: Covered by the Epitomee® FDA clearance (adults with BMI 25-40)

Within FDA-cleared indication

Prefer a non-drug option

Want to avoid injections, hormones and drugs absorbed into the body

Epitomee® fit: Not absorbed, no hormones, same dose from day 1; 1.4% stopped due to side effects


RESET pivotal trial

epitomee® weight management capsule

Epitomee® has not been studied in patients after stopping a GLP-1 drug. Sources: Epitomee® FDA 510(k) K240544; Wegovy®/Zepbound® U.S. prescribing information; Kushner et al., Int J Obes 2026; Epitomee® U.S. Physician IFU; Rodriguez et al., JAMA Netw Open 2025; Gasoyan et al., Obesity 2025; Wilding et al., Diabetes Obes Metab 2022; Kamar et al., Obes Pillars 2025.


US TeleHealth Go-to-Market Strategy

A streamlined operation driven by targeted digital marketing and telehealth platform



Discovery

Targeted DTC ads via Meta, Google, PR and Email/SMS reach high-intent audiences




Intake and Prescription

Asynchronous telehealth clinical intake and review by a licensed HCP



Fulfillment

If clinically appropriate, the provider issues a prescription; a licensed pharmacy owned by ReviveHealth fulfills the order



Deliver

Epitomee Capsule shipped directly to the patient's doorstep

Technology stack: licensed telehealth provider network with asynchronous consultation platform · licensed pharmacy fulfillment partner · identity & age verification · payment pre-authorization pending provider approval

Sample DTC Ad Creatives









US 1st B2B Partnership: ReviveHealth

What is ReviveHealth? An employer health-benefits and virtual-care platform for US employers, serving 3,000+ organizations and 4M+ members*. A licensed pharmacy owned by ReviveHealth is also the dispensing pharmacy for Epitomee's US direct-to-consumer telehealth channel.

ReviveHealth partnership

- **Integrating the Epitomee® capsule into the weight program.**
- **Potential employer-sponsored coverage,** subject to plan design
- **Full Clinical Integration:** Prescribing, coaching, and pharmacy delivery managed via one digital dashboard.
- **Early-stage implementation**



*Revive website (revive.health), accessed October 2026.

Commercial Rollout: OUS

EXPANSION THROUGH LOCAL DISTRIBUTORS

1 **Israel**
Home market

2 **Europe**

epitomee
weight management capsule

Epitomee Targeting Large Opportunity in Israel Home Market

THE OPPORTUNITY

Almost 60%

of Israelis are Overweight or Obese*

63% of Israeli men are overweight/obese*

57% of Israeli women are overweight/obese*

GO-TO-MARKET: ISRAEL - THE HOME-BASE MARKET

Exclusive Distributor in Israel

Epitomee Partnered with Rafa, a pharmaceutical company and distributor, Rx and OTC, manufacturing, logistics and marketing.

✓ Commercial Status

- Pre-launch activities completed with first orders delivered to Rafa
- Currently fulfilling first orders

Operating Model

Traditional pharmaceutical distribution strategy.

Transfer price to Epitomee®

Distributor activities and 3rd parties:

- Local pharmacy chains
- Online pharmacy
- Currently: Local conferences and meetings with 4800 Family Physicians, 200 Endocrinologists

*Knesset Research and Information Center, 'Overweight and Obesity' (Feb 2023); adults aged 20-64, 2021 data; as reported by Doctors Only, 28.2.2023

Capturing the European Market Opportunity

$8.1B	$22.5B	12.1% CAGR
European GLP-1 market, all indications incl. T2D (2025)*	Projected European GLP-1 market by 2033 (incl. T2D)*	Projected growth through 2033*

OUR GO-TO-MARKET STRATEGY

1 Market Approach

Localized strategies tailored to each territory in the European market

2 Distribution Partners

Partnering with early-adopter distributors

3 Operations

Each distributor owns its territory end-to-end:

- Marketing investment
- Logistics & supply chain
- Sales execution


Epitomee sells at transfer price

epitomee

* https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/europe; including T2D patients

Manufacturing Scale-Up

Scaling production to support commercial growth



epitomee®
weight management capsule

State-of-the-Art Production Process



1 **Raw material**




2 **Thin film coating**



3 **Robotic assembly**

Estimated Manufacturing Capacity: Scale-Up Plan



Forward-looking information. The capacity estimates in this slide, including the expected capacity at the end of 2026, approximately 15M capsules in 2027 without additional capital, and capacity levels beyond 2027, constitute forward-looking information, as defined in the Israeli Securities Law, 5728-1968. They are based on management's current production plan and estimates, the existing equipment and the Company's three operating sites in Israel, as of the Presentation Date, and are subject to change. Capacity beyond 2027 requires additional capital expenditure and production expansion and is subject to funding. Actual output may differ materially due to factors including production yields and equipment performance, availability of raw materials, workforce and operational constraints, quality and regulatory requirements, and supply-chain or logistical disruptions. Expanded capacity does not necessarily result in proportional sales growth. These figures are illustrative and do not constitute a forecast, target or guidance.

Next Steps

ACCELERATING GROWTH

Growth roadmap

epitomee
weight management capsule

On Track for Achievable Growth in Fast-Growing Weight Management Market

1 Home Market Launch

Exclusive distribution agreement with Rafa; pre-launch completed and first orders delivered

Next: Expand marketing to broader target audience

2 Global Expansion: ROW & EU

Distribution agreements signed; product shipped to Germany, Spain and Chile

Next: Expand partnerships and geographies

3 Manufacturing Scale-Up

Automated production validated and approved by the EU notified body

Next: Streamline manufacturing for maximum efficiency and scalability

4 US B2B Partnerships

First B2B agreement signed with ReviveHealth (employer weight program)

Next: Expand B2B partnerships and patient access

5 US Direct-to-Consumer Telehealth

DTC platform launched (mid Oct 2026) with telehealth and pharmacy partners; paid social ads started

Next: First direct sales and campaign optimization

Built on strong foundation

peer-reviewed clinical data, regulatory approvals, integrated manufacturing

epitomee

*The “Next” items constitute forward-looking information, as defined in the Israeli Securities Law, 5728-1968, based on management’s current plans and estimates as of the Presentation Date. They may not materialize, in whole or in part, or may materialize differently, due to factors including the availability of financing, regulatory requirements, market acceptance, the performance of and agreements with third parties, and the risk factors described in the Company’s 2025 Annual Report.

Why Epitomee, Why Now

FDA-cleared product

FDA-cleared (Sept 2024), CE-marked and registered with AMAR; non-drug Rx capsule for adults with BMI 25-40

Proven clinical results

RESET: ×2.5 more patients lost ≥10% (27% vs. 11%)[1]; selected RESET participants who completed 24 weeks of Epitomee® treatment and achieved ≥3% weight loss maintained mean weight loss of 11.2% through week 48 in the ELECT extension study[2]

Significant target market

172M eligible US patients[3]; weight-management market of ~$180B (2025)[4]

Manufacturing infrastructure in place

3 operating sites in Israel; automated production validated and approved by the EU notified body; annual capacity of ~15M capsules in 2027 without additional capital*

New CEO with a proven track record

Dolev Rafaeli, PhD (Aug 2026): former CEO of Radiancy, PhotoMedex (NASDAQ: PHMD) and Strata Skin Sciences (NASDAQ: SSKN)

Commercialization underway

Israel launched with Rafa; US: first B2B agreement signed (ReviveHealth); DTC telehealth platform launched (mid Oct 2026), paid social advertising underway

1. Ard et al., Obesity 2025 (RESET). 2. Kamar et al., Obes Pillars 2025 (ELECT). 3. BCG analysis commissioned by the Company (June 2024). 4. Towards Healthcare, Weight Management Market report 2026.

*Forward-looking information, as defined in the Israeli Securities Law, 5728-1968. The expected manufacturing capacity of approximately 15M capsules in 2027 is based on management's current production plan and estimates, the existing equipment and the Company's three operating sites in Israel, as of the Presentation Date. Actual capacity may differ materially due to factors including production yields and equipment performance, availability of raw materials and components, workforce and operational constraints, quality and regulatory requirements, and supply-chain disruptions. Capacity does not necessarily translate into proportional sales. Further scale-up beyond the 2027 plan requires additional capital expenditure and is subject to funding.

epitomee®

Thank you

